ReviewCurrent oncology reports2006
Methadone for treatment of cancer pain.
Review in Current oncology reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 31 citations in OpenAlex.
- Pain Management in Animals with Oncological Disease: Opioids as Influencers of Immune and Tumor Cellular Balance.Cancers · 2024Review
- Treatment of painful calciphylaxis with methadone in a palliative care unit: A case report.Clinical nephrology. Case studies · 2023Article
- Methadone switching for refractory cancer pain.BMC palliative care · 2022Article
- Methadone as first-line opioid treatment for cancer pain in a developing country palliative care unit.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Pharmacological options for the management of refractory cancer pain-what is the evidence?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Review
- Cancer Pain Management and Bone Metastases: An Update for the Clinician.Breast care (Basel, Switzerland) · 2012Article
- Intraoperative methadone: rediscovery, reappraisal, and reinvigoration?Anesthesia and analgesia · 2011Article
- Interindividual variability of methadone response: impact of genetic polymorphism.Molecular diagnosis & therapy · 2008Review
- Methadone prolongs cardiac conduction in young patients with cancer-related pain.Journal of opioid managementArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methadone is a unique mu opioid agonist, which also has delta receptor affinity and properties of N-methyl-D-aspartate receptor antagonism and monoamine reuptake inhibition. It is mainly used in the setting of uncontrolled pain or dose-limiting toxicity. Caution is advised when switching to methadone, especially from high doses of previous opioid, due to its variable conversion ratio and the potential for delayed toxicity due to its long half-life. Increasing evidence of risk also exists for a prolonged QT interval and torsades de pointes with very large doses of methadone. Methadone is likely safer when used at lower doses as a first-line opioid, but its potential as such has not received enough formal evaluation. Randomized controlled trials are needed to assess the effectiveness and safety of methadone compared with other opioids and to further evaluate its role in the treatment of neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.